CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE
CCTN - 避孕临床试验网络 - 核心 - 女性
基本信息
- 批准号:8887061
- 负责人:
- 金额:$ 1.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-06-26 至 2015-06-25
- 项目状态:已结题
- 来源:
- 关键词:Basic ScienceChemicalsChildChild health careClinical ResearchClinical TrialsClinical Trials NetworkContraceptive AgentsContraceptive methodsContractsDevelopmentDevicesDrug FormulationsFemaleFemale Contraceptive AgentsGoalsGrantGynecologicHealth educationHuman DevelopmentInstitutesLeadLeiomyomaMale Contraceptive AgentsMethodsNational Institute of Child Health and Human DevelopmentPharmaceutical PreparationsPhasePopulation ResearchProtocols documentationReproductive HealthSafetySiteSocial WelfareTestingUnited States Food and Drug AdministrationUnited States National Institutes of HealthWomanbaseclinical research siteclinical trial phase II/III/IVdrug candidateendometriosispre-clinicalresearch and developmentsynthetic peptidetreatment trial
项目摘要
The National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), is the lead Federal agency for the conduct of basic and clinical research to develop new contraceptives and to evaluate existing methods of contraception and reproductive health. The Center for Population Research (CPR), within NICHD, was established in 1968 by the Secretary of Health Education and Welfare, with the important goal of developing new
contraceptives through the use of contracts and grants. Within CPR, the Contraception and Reproductive Health Branch (CRHB) has long supported several preclinical contraceptive testing facilities as well as facilities for synthetic chemical and synthetic peptide formulation. To further expand their contraceptive development capabilities, in 1996 CRHB established the NICHD Contraceptive Clinical Trials Network (CCTN). The current CCTN has conducted Phase I, II, and III
clinical trials of both female and male contraceptive methods. With the recompetition of the CCTN, clinical sites will perform Phase I, II, III, and Phase IV clinical trials of a wide variety of new or existing female contraceptive methods.
美国国立卫生研究院(NIH),尤尼斯·肯尼迪·施莱佛国家儿童健康和人类发展研究所(NICHD),是进行基础和临床研究以开发新的避孕药具和评估现有避孕方法和生殖健康的牵头联邦机构。1968年,卫生、教育和福利部长在NICHD内设立了人口研究中心,其重要目标是开发新的人口研究项目。
通过合同和赠款提供避孕药具。在避孕和生殖健康方案内,避孕和生殖健康分支(CRHB)长期以来一直支持几个临床前避孕测试设施以及合成化学品和合成肽制剂设施。为了进一步扩大其避孕药具开发能力,CRHB于1996年建立了NICHD避孕药具临床试验网络。目前的CCTN已经进行了第一阶段,第二阶段和第三阶段
女性和男性避孕方法的临床试验。随着CCTN的重新竞争,临床研究中心将对各种新的或现有的女性避孕方法进行I期、II期、III期和IV期临床试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANITA NELSON其他文献
ANITA NELSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANITA NELSON', 18)}}的其他基金
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM-NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK-FEMALE SITES-CORE FUNCTION ACTIVITIES
CCTN-避孕发展计划-NICHD避孕临床试验网络-女性站点-核心功能活动
- 批准号:
10896887 - 财政年份:2020
- 资助金额:
$ 1.95万 - 项目类别:
CCTN-CONTRACEPTIVE DEVELOPMENT PROGRAM-NICHD CONTRACEPTIVE CLINICAL TRIALS NETWORK-FEMALE SITES-CORE FUNCTION ACTIVITIES
CCTN-避孕发展计划-NICHD避孕临床试验网络-女性站点-核心功能活动
- 批准号:
10243451 - 财政年份:2020
- 资助金额:
$ 1.95万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIAL NETWORK -- FEMALE SITES
CCTN - 避孕临床试验网络 - 女性站点
- 批准号:
10329727 - 财政年份:2014
- 资助金额:
$ 1.95万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIAL NETWORK -- FEMALE SITES
CCTN - 避孕临床试验网络 - 女性站点
- 批准号:
10198646 - 财政年份:2014
- 资助金额:
$ 1.95万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIAL NETWORK -- FEMALE SITES
CCTN - 避孕临床试验网络 - 女性站点
- 批准号:
8935086 - 财政年份:2014
- 资助金额:
$ 1.95万 - 项目类别:
CCTN - CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL ULIPRISTAL ACETATE
CCTN - 每日口服醋酸乌利司他的避孕功效和安全性
- 批准号:
10078225 - 财政年份:2013
- 资助金额:
$ 1.95万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - CORE - FEMALE
CCTN - 避孕临床试验网络 - 核心 - 女性
- 批准号:
9046505 - 财政年份:2013
- 资助金额:
$ 1.95万 - 项目类别:
INDICATIONS AND OUTCOME OF REPEAT C SECTION AT HARBOR-UCLA, 1987-1990
1987-1990 年在 HARBOR-UCLA 进行重复 C 部分的适应症和结果
- 批准号:
6416409 - 财政年份:2000
- 资助金额:
$ 1.95万 - 项目类别:
INDICATIONS AND OUTCOME OF REPEAT C SECTION AT HARBOR-UCLA, 1987-1990
1987-1990 年在 HARBOR-UCLA 进行重复 C 部分的适应症和结果
- 批准号:
6306696 - 财政年份:1999
- 资助金额:
$ 1.95万 - 项目类别:
INDICATIONS AND OUTCOME OF REPEAT C SECTION AT HARBOR-UCLA, 1987-1990
1987-1990 年在 HARBOR-UCLA 进行重复 C 部分的适应症和结果
- 批准号:
6219959 - 财政年份:1998
- 资助金额:
$ 1.95万 - 项目类别:
相似海外基金
A Personalized Digital Intervention Program to Reduce Exposure to Endocrine Disrupting Chemicals among a Child-Bearing Age Cohort
个性化数字干预计划,以减少育龄人群接触内分泌干扰化学物质的机会
- 批准号:
10699889 - 财政年份:2022
- 资助金额:
$ 1.95万 - 项目类别:
Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals (EDCs) in Women of Child-Bearing Age and their Partners
个性化移动干预减少育龄妇女及其伴侣接触内分泌干扰化学物质 (EDC)
- 批准号:
10484791 - 财政年份:2022
- 资助金额:
$ 1.95万 - 项目类别:
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
生命早期接触内分泌干扰化学物质与儿童生长、肥胖和神经发育
- 批准号:
10469410 - 财政年份:2016
- 资助金额:
$ 1.95万 - 项目类别:
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
生命早期接触内分泌干扰化学物质与儿童生长、肥胖和神经发育
- 批准号:
10239160 - 财政年份:2016
- 资助金额:
$ 1.95万 - 项目类别:
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
生命早期接触内分泌干扰化学物质与儿童生长、肥胖和神经发育
- 批准号:
10745230 - 财政年份:2016
- 资助金额:
$ 1.95万 - 项目类别:
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
生命早期接触内分泌干扰化学物质与儿童生长、肥胖和神经发育
- 批准号:
10205624 - 财政年份:2016
- 资助金额:
$ 1.95万 - 项目类别:
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
生命早期接触内分泌干扰化学物质与儿童生长、肥胖和神经发育
- 批准号:
9726480 - 财政年份:2016
- 资助金额:
$ 1.95万 - 项目类别:
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment
生命早期接触内分泌干扰化学物质与儿童生长、肥胖和神经发育
- 批准号:
10002319 - 财政年份:2016
- 资助金额:
$ 1.95万 - 项目类别:
Endocrine Disrupting Chemicals, Thyroid Hormones, and Child Neurobehavior
内分泌干扰化学物质、甲状腺激素和儿童神经行为
- 批准号:
8887432 - 财政年份:2015
- 资助金额:
$ 1.95万 - 项目类别:
Endocrine Disrupting Chemicals, Thyroid Hormones, and Child Neurobehavior
内分泌干扰化学物质、甲状腺激素和儿童神经行为
- 批准号:
9248209 - 财政年份:2015
- 资助金额:
$ 1.95万 - 项目类别: